Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 20/20 | 0.46 |
| ▸ | FPR3 | P25089 | 2/20 | 0.39 |
| ▸ | TSPO | P30536 | 2/20 | 0.39 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5844615 | 0.69 | SIGMAR1 (0.39) | CRHR1 | |
| SCHEMBL7354022 | 0.68 | CRHR1 (0.44) | CRHR1 | |
| SCHEMBL21208882 | 0.67 | CRHR1 (0.42) | CRHR1FPR3TSPOTMEM97TDP1 | |
| SCHEMBL9747604 | 0.66 | CRHR1 (0.49) | CRHR1TDP1 | |
| SCHEMBL5788442 | 0.65 | CRHR1 (0.52) | CRHR1FPR3TSPOTMEM97 | |
| SCHEMBL11934265 | 0.65 | CRHR1 (0.41) | CRHR1FPR3TSPOTMEM97TDP1 | |
| SCHEMBL22082128 | 0.65 | CRHR1 (0.40) | CRHR1FPR3TSPOTMEM97TDP1 | |
| SCHEMBL12250806 | 0.65 | TERT (0.48) | CRHR1TDP1 | |
| SCHEMBL5786586 | 0.64 | CRHR1 (0.73) | CRHR1 | |
| SCHEMBL799732 | 0.64 | CRHR1 (0.53) | CRHR1FPR3TSPOTMEM97TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6956047-B1 | Corticotropin releasing factor antagonists | PFIZER INC. (US) | 2005-10-18 | — | — | US | claimed |
| EP-0764166-B1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | PFIZER (US) | 2000-09-13 | — | — | EP | claimed |
| EP-0773023-A1 | New uses for corticotropin releasing factor (CRF) antagonists | PFIZER INC. (US) | 1997-05-14 | — | — | EP | claimed |
| EP-0764166-A1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | PFIZER INC. (US) | 1997-03-26 | — | — | EP | claimed |
| WO-1995033750-A1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | PFIZER INC. (US) | 1995-12-14 | — | — | WO | claimed |
| US-7125880-B1 | Corticotropin releasing factor antagonists | PFIZER INC. (US) | 2006-10-24 | — | — | US | disclosed |
| US-7067664-B1 | Corticotropin releasing factor antagonists | PFIZER INC. (US) | 2006-06-27 | — | — | US | disclosed |
| US-6956047-B1 | Corticotropin releasing factor antagonists | PFIZER INC. (US) | 2005-10-18 | — | — | US | disclosed |
| US-20050032846-A1 | Corticotropin releasing factor antagonists | PFIZER INC. | 2005-02-10 | — | — | US | disclosed |
| US-6844351-B1 | Corticotropin releasing factor antagonists | PFIZER INC. (US) | 2005-01-18 | — | — | US | disclosed |
| US-20020094992-A1 | Intermittent administration of a growth hormone secretagogue | MACLEAN DAVID B (US) | 2002-07-18 | — | — | US | disclosed |
| EP-1186293-A2 | Intermittent administration of a growth hormone secretagogue | Pfizer Products Inc. (US) | 2002-03-13 | — | — | EP | disclosed |
| EP-0764166-B1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | PFIZER (US) | 2000-09-13 | — | — | EP | disclosed |
| EP-0773023-A1 | New uses for corticotropin releasing factor (CRF) antagonists | PFIZER INC. (US) | 1997-05-14 | — | — | EP | disclosed |
| EP-0764166-A1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | PFIZER INC. (US) | 1997-03-26 | — | — | EP | disclosed |
| WO-1995033750-A1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | PFIZER INC. (US) | 1995-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032846-A1 | Corticotropin releasing factor antagonists | CRH, CRHR2, CRHR1 | CRHR1 3/4885FPR3 288/4885TSPO 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.